Last updated: August 24, 2026
Menopur is a mature, globally marketed fertility biologic-drug product based on human menopausal gonadotropin, or menotropins. Ferring Pharmaceuticals owns and markets the product in major assisted-reproduction markets. Its commercial position rests on established use in controlled ovarian stimulation and, in the United States, on a differentiated urinary-derived gonadotropin profile rather than on patent exclusivity.
Menopur revenue is not separately disclosed by Ferring. Ferring is privately held and reports limited product-level financial information. The product’s financial trajectory is therefore best assessed through fertility-market growth, treatment-volume trends, competitive pricing, regulatory barriers, and the absence of meaningful late-life patent protection.
What is Menopur and how does it work?
Menopur is a menotropin product containing follicle-stimulating hormone, or FSH, and luteinizing hormone, or LH, activity. It is used primarily for:
- Controlled ovarian stimulation in patients undergoing assisted reproductive technology, including in vitro fertilization.
- Induction of ovulation in selected patients with anovulation who have not responded adequately to clomiphene citrate.
Menopur is administered by subcutaneous injection in the United States. It is supplied in single-dose vials in 75 international-unit formulations. The product is reconstituted before injection and is dosed according to ovarian response and treatment protocol. [1]
Menotropins are derived from the urine of postmenopausal women and undergo purification and standardization. This distinguishes Menopur from recombinant gonadotropins such as follitropin alfa, follitropin beta, and follitropin delta.
What is Menopur’s FDA regulatory status?
The U.S. Food and Drug Administration approved Menopur under New Drug Application 021663. It is regulated as a drug under an NDA rather than as a biologic licensed under a Biologics License Application. The regulatory pathway means that a competing product generally would pursue an abbreviated new drug application, subject to demonstrating pharmaceutical equivalence and bioequivalence where applicable, rather than a biosimilar application under the Public Health Service Act. [1, 2]
Menopur is therefore often described commercially as a fertility biologic or biologically derived product, but it does not have the same statutory exclusivity framework as an FDA-approved monoclonal antibody or other BLA product.
How large is the market for Menopur?
Menopur participates in the global gonadotropin and assisted-reproduction market. Market demand is driven by:
- Growth in IVF and intracytoplasmic sperm injection procedures.
- Increasing maternal age at first birth.
- Greater use of fertility preservation.
- Expanded insurance coverage in selected U.S. states and international markets.
- Increased diagnosis and treatment of male and female infertility.
- Rising use of fertility services by same-sex couples and single intended parents.
The product is exposed to a broader market than the number of IVF cycles alone because gonadotropins are also used for ovulation induction and other reproductive endocrinology protocols.
The market is mature in North America and Western Europe but continues to develop in parts of Asia-Pacific, Latin America, and the Middle East. Treatment access, reimbursement, clinic capacity, drug procurement practices, and regulatory restrictions create substantial geographic variation.
What is driving Menopur demand?
Menopur demand is linked to treatment volumes rather than to chronic daily use. Each patient typically receives a limited stimulation course, creating a repeatable but episodic revenue model. The main demand variables are:
| Demand driver |
Effect on Menopur |
| IVF cycle growth |
Positive |
| Fertility insurance expansion |
Positive |
| Older average maternal age |
Positive |
| Increased competition among clinics |
Mixed, with possible price pressure |
| Single-embryo-transfer protocols |
Mixed; may reduce some medication intensity |
| Oral ovarian stimulation alternatives |
Negative in selected ovulation-induction patients |
| Recombinant gonadotropin competition |
Negative to mixed |
| Generic or biosimilar entry |
Potentially negative, although no conventional biosimilar pathway applies |
ASRM reported that U.S. assisted-reproductive technology activity remains substantial, with more than 300,000 assisted-reproduction cycles reported annually in recent reporting periods. The Centers for Disease Control and Prevention also tracks a large and expanding U.S. fertility-treatment system. [3, 4]
How does Menopur compare with competing fertility drugs?
Menopur competes primarily with recombinant and urinary-derived gonadotropins. The relevant products differ in FSH/LH composition, manufacturing method, dosing conventions, device design, physician familiarity, and contracting terms.
| Product |
Active ingredient or class |
Principal company |
Commercial position |
| Menopur |
Human menopausal gonadotropin, FSH and LH activity |
Ferring |
Established urinary-derived product |
| Gonal-F |
Follitropin alfa |
Organon, following transfer of certain Merck products in some markets |
Major recombinant FSH competitor |
| Follistim AQ |
Follitropin beta |
Organon |
Recombinant FSH competitor |
| Rekovelle |
Follitropin delta |
Ferring |
Recombinant FSH product with individualized dosing approach |
| Bravelle |
Urofollitropin |
Ferring historically |
Urinary-derived FSH product; market availability varies |
| Merional and related products |
Menotropins |
Regional manufacturers |
Lower-price competition in certain markets |
Ferring’s portfolio creates both defensive and cannibalization dynamics. Menopur gives Ferring exposure to the established urinary-derived segment, while Rekovelle gives it a recombinant product positioned around individualized dosing. Physicians and clinics may select between products based on treatment protocol, patient characteristics, local reimbursement, procurement contracts, and total cycle cost.
How does Menopur compare with Gonal-F and Follistim?
Menopur contains both FSH and LH activity, while Gonal-F and Follistim are principally recombinant FSH products. This difference supports product segmentation but does not eliminate substitution. Fertility specialists may use Menopur alone, combine recombinant FSH with LH activity, or select a recombinant FSH product depending on ovarian-reserve profile and clinical protocol.
Commercial competition is often decided at the clinic or distributor level. Large fertility networks can negotiate discounts and rebates, reducing manufacturers’ realized prices even when list prices remain stable.
What patents protect Menopur?
Menopur’s principal commercial protection is no longer based on a strong active patent estate. The product was approved in the United States in 2004, and any original chemical, formulation, or use patents associated with the product would generally have expired or reached the end of their effective terms by the mid-2020s.
What is the Orange Book status of Menopur?
Menopur is listed in the FDA’s Orange Book as an NDA product. The Orange Book is the relevant FDA publication for approved drug products and their listed patents. Because Menopur is an NDA drug rather than a BLA biologic, it is not primarily evaluated through the Purple Book’s biosimilar interchangeability framework. [2, 5]
The commercial importance of the Orange Book position is limited at this stage because Menopur’s original market exclusivity and likely core patent protection have expired. Product-specific device, packaging, manufacturing, or process claims could still affect competition, but those protections are narrower than an active composition-of-matter patent.
When did Menopur lose exclusivity?
Menopur lost its principal regulatory exclusivity long ago. The original U.S. approval dates to 2004, and the product is now a mature branded medicine. FDA orphan-drug exclusivity does not apply because Menopur is not an orphan-designated product for its principal reproductive indications.
The current competitive question is not whether an original exclusivity period remains. It is whether a competing manufacturer can obtain approval, achieve consistent supply, meet quality requirements, and secure distribution and clinic contracts.
Are there Paragraph IV challenges to Menopur?
Publicly visible Paragraph IV litigation has not become a major commercial event for Menopur comparable to litigation surrounding high-revenue small-molecule drugs. No widely reported, market-shifting Paragraph IV challenge has displaced Ferring’s U.S. franchise.
A Paragraph IV filing could theoretically target an Orange Book-listed patent. The practical risk is constrained by several factors:
- Menopur’s mature product profile.
- The complexity of urinary-derived gonadotropin manufacturing.
- The need to demonstrate consistent potency and quality.
- Limited ability to rely on a conventional simple-generic substitution model.
- The importance of fertility-clinic purchasing relationships.
- Manufacturing and supply-chain requirements for human-derived starting material.
The absence of major public Paragraph IV litigation does not mean competition is impossible. It means that regulatory and manufacturing execution may be more important barriers than patent litigation.
What formulation and manufacturing protections affect Menopur?
Menopur’s most relevant protection is operational rather than purely legal. The product requires control over:
- Collection and qualification of human urinary starting material.
- Purification of gonadotropin fractions.
- Standardization of FSH and LH activity.
- Viral and microbial safety controls.
- Batch consistency.
- Sterility and fill-finish operations.
- Reconstitution and packaging.
- Global regulatory compliance.
These requirements can limit the number of credible suppliers. A competitor may be able to design around an expired patent yet still face high development costs, validation requirements, uncertain yield, and difficulty matching commercial scale.
Ferring’s manufacturing and regulatory history can therefore support price retention after patent expiry. This type of barrier is weaker than an enforceable composition patent because it does not prevent entry. It can delay entry and raise the cost of achieving reliable supply.
What is Menopur’s financial trajectory?
Menopur is likely in the mature-to-late-growth phase of its lifecycle. Ferring does not publish a separate Menopur revenue line, earnings contribution, gross margin, or geographic sales breakdown. Public financial analysis must therefore use portfolio-level information and market indicators rather than verified product revenue.
The likely trajectory has four stages:
1. Expansion after U.S. approval
Menopur gained commercial traction as an established gonadotropin option in IVF and ovulation-induction protocols. Physician familiarity and Ferring’s reproductive-medicine infrastructure supported uptake.
2. Portfolio maturity
The product became an anchor of Ferring’s reproductive-medicine business. Mature fertility products generally generate recurring revenue because treatment cycles continue even after core patents expire.
3. Price and mix pressure
The product faces pressure from:
- Recombinant FSH products.
- Urinary-derived alternatives.
- Regional tender systems.
- Fertility-clinic purchasing groups.
- Distributor discounts.
- Reimbursement constraints.
- Potential future abbreviated-approval competitors.
Volume growth in IVF can offset some price erosion, but that offset depends on market and contract mix.
4. Long-term stabilization or gradual erosion
The most probable base-case trajectory is stable-to-moderately declining net revenue in mature markets, with selected growth in developing fertility markets. Menopur can remain commercially relevant without delivering the growth profile of a newly launched specialty medicine.
A reasonable business interpretation is:
| Factor |
Financial effect |
| Rising IVF procedure volume |
Supports revenue |
| Established physician use |
Supports retention |
| Expired core exclusivity |
Limits pricing power |
| Few qualified suppliers |
Supports margins and continuity |
| Recombinant competition |
Limits share growth |
| Clinic and payer discounts |
Reduces net price |
| Ferring portfolio cross-selling |
Supports account retention |
| Manufacturing complexity |
Raises cost but may deter entry |
No reliable public source supports a precise Menopur revenue estimate. Ferring’s private ownership structure prevents the market from measuring product-level sales with the precision available for publicly traded competitors.
What is Menopur’s revenue exposure to Ferring?
Menopur is strategically important because it is part of Ferring’s reproductive-medicine franchise, one of the company’s established therapeutic platforms. Its value extends beyond direct sales:
- It gives Ferring access to IVF clinics and reproductive endocrinologists.
- It supports commercial relationships with fertility distributors.
- It complements Ferring’s reproductive products, including Rekovelle in markets where available.
- It provides recurring demand linked to fertility-treatment cycles.
- It broadens Ferring’s exposure across urinary-derived and recombinant gonadotropin categories.
The product is unlikely to be a high-growth asset. Its financial value is more consistent with a durable cash-generating brand whose performance depends on treatment-volume growth and supply reliability.
What generic entry risks exist for Menopur?
Menopur’s generic-entry risk is moderate but difficult to quantify. The principal risks are regulatory and manufacturing rather than a near-term wave of automatic pharmacy substitution.
Near-term risk
Near-term risk is limited by the absence of a clearly established high-volume competing product that has rapidly displaced Menopur in the United States. Existing competition is primarily therapeutic and commercial rather than a direct generic substitution event.
Medium-term risk
Medium-term risk increases if a competitor demonstrates:
- Consistent menotropin potency.
- A scalable urinary collection network.
- Acceptable impurity and safety profiles.
- FDA approval through an abbreviated or hybrid pathway.
- Reliable supply during fertility-treatment cycles.
- Favorable pricing to large fertility networks.
Launch scenarios
| Scenario |
Expected effect on Menopur |
| No direct U.S. generic entrant |
Stable volume, gradual price pressure |
| One approved competitor |
Discounting and selective share loss |
| Multiple competitors |
Faster net-price erosion and clinic switching |
| Supply disruption at a competitor |
Temporary Menopur volume benefit |
| Continued IVF growth with limited entry |
Volume offsets price erosion |
An entrant would probably launch through specialty distributors, fertility-clinic contracts, and payer channels rather than depend solely on retail pharmacy substitution.
Which companies are challenging Menopur commercially?
The strongest competitive pressure comes from manufacturers with established fertility portfolios:
- Organon, through Gonal-F and Follistim in relevant markets.
- Ferring itself, through Rekovelle and other reproductive-medicine products.
- Regional manufacturers of menotropins and urinary-derived gonadotropins.
- Fertility-focused manufacturers supplying lower-cost products in markets outside the United States.
The competitive landscape is fragmented by geography. A product with limited U.S. penetration may still compete aggressively in Europe, Asia, Latin America, or the Middle East through national tenders and private-clinic procurement.
What licensing deals affect Menopur?
Ferring owns the Menopur brand and commercializes it through its global operating structure. Publicly disclosed licensing information is more prominent for some of Ferring’s other assets than for Menopur itself. No major current third-party licensing transaction is necessary to explain Menopur’s U.S. commercial position.
Distribution and commercialization arrangements may vary by country. Those agreements can affect net sales, but Ferring does not provide a public, product-level geographic accounting that permits reliable attribution.
What litigation and settlement agreements affect Menopur?
Menopur has not generated a publicly dominant patent-litigation narrative in the manner of leading oncology, immunology, or diabetes brands. There is no widely reported settlement agreement that establishes a material delayed generic-entry date for the U.S. product.
The litigation risk is therefore lower than the commercial risks created by:
- Product-quality investigations.
- Supply interruptions.
- Manufacturing deviations.
- Distributor disputes.
- Advertising or promotional compliance.
- Procurement-contract pressure.
For a mature fertility product, a manufacturing interruption could have a faster revenue effect than a patent lawsuit because fertility treatment cycles are time-sensitive and clinics may switch products quickly when supply is unavailable.
How strong is the Menopur patent estate?
Menopur’s patent estate is weak as a source of current exclusivity and moderate as a source of practical commercial protection.
| Protection category |
Current assessment |
| Core composition patent |
Mature or expired |
| Regulatory exclusivity |
Expired |
| Method-of-use protection |
Limited current commercial significance |
| Formulation protection |
Potentially narrow and product-specific |
| Manufacturing know-how |
More important than patent exclusivity |
| Brand and physician familiarity |
Meaningful commercial value |
| Supply-chain infrastructure |
Meaningful barrier to entry |
| Device or packaging claims |
Possible but unlikely to block broad competition |
Menopur’s residual moat is based on manufacturing know-how, regulatory history, physician experience, supply reliability, and clinic relationships. Those protections can preserve cash flow but do not justify premium-growth assumptions.
What is the outlook for Menopur through the late 2020s?
The base case is a mature branded product with resilient demand and gradual commercial pressure.
Base case
IVF-cycle growth and fertility-treatment expansion support stable unit demand. Net pricing declines modestly as clinics negotiate harder and recombinant products compete for share. Revenue is broadly stable to moderately lower in mature markets.
Upside case
Higher IVF utilization, expanded reimbursement, fertility-preservation growth, and supply constraints affecting competitors increase Menopur volume. Ferring maintains share through reliable supply and portfolio contracting.
Downside case
A direct competitor obtains approval, clinics consolidate purchasing, and payers favor lower-cost alternatives. Menopur experiences faster price erosion and reduced use in protocols that favor recombinant FSH.
The key financial variables are unit volume, net price after rebates, geographic mix, manufacturing cost, and the pace of direct competition. Patent expiry is already reflected in the product’s mature-market profile.
Key Takeaways
- Menopur is Ferring’s established menotropin product for IVF and ovulation induction.
- It is an NDA-approved drug, not a conventional BLA biologic subject to the biosimilar pathway.
- Core regulatory exclusivity and likely original patent protection have expired.
- Ferring does not disclose Menopur product-level revenue.
- Demand benefits from IVF growth, fertility preservation, and broader infertility treatment.
- Pricing is constrained by recombinant gonadotropins, regional urinary-derived products, clinic purchasing groups, and reimbursement.
- Manufacturing complexity and supply reliability are more important current barriers than patent rights.
- The likely financial trajectory is stable-to-moderately declining revenue in mature markets, with selective growth in emerging fertility markets.
- No major public Paragraph IV challenge or settlement currently defines the Menopur franchise.
- Menopur remains commercially valuable as a durable reproductive-medicine brand, but it is not a high-growth exclusivity asset.
FAQs About Menopur Market and Financial Outlook
Is Menopur a biologic drug or a generic drug?
Menopur is a biologically derived menotropin product approved under an NDA. It is not a biosimilar and is not itself a generic product.
Who owns Menopur?
Ferring Pharmaceuticals owns and markets Menopur globally, subject to country-specific commercial and distribution arrangements.
Does Menopur have active U.S. patent protection?
Menopur’s original exclusivity framework is mature. Current commercial protection is more likely to arise from manufacturing capability, regulatory know-how, supply reliability, and brand relationships than from a broad active composition patent.
Can Menopur be automatically substituted at the pharmacy?
Automatic substitution depends on the competing product, FDA approval pathway, state law, payer policy, and product-specific equivalence determinations. Menopur competition is more likely to arise through physician choice and fertility-clinic procurement than through ordinary generic substitution.
Is Menopur revenue growing?
Ferring does not report Menopur revenue separately. Market fundamentals support demand, but the product’s mature lifecycle and competitive pricing indicate a stable-to-moderately declining revenue profile in established markets rather than sustained high growth.
References
- U.S. Food and Drug Administration. (2024). Menopur prescribing information. FDA.
- U.S. Food and Drug Administration. (2024). Drugs@FDA: Menopur, NDA 021663. FDA.
- Centers for Disease Control and Prevention. (2024). 2022 assisted reproductive technology fertility clinic and national summary report. U.S. Department of Health and Human Services.
- American Society for Reproductive Medicine. (2024). Assisted reproductive technology and fertility treatment data. ASRM.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, 44th edition. FDA.
